From Wikipedia, the free encyclopedia
Jump to: navigation, search
Trifluridine structure.svg
Systematic (IUPAC) name
1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5- (trifluoromethyl) pyrimidine-2,4-dione
Clinical data
Trade names Viroptic
AHFS/ Monograph
  • US: C (Risk not ruled out)
Routes of
Eye drops
Legal status
Legal status
Pharmacokinetic data
Biological half-life 12 minutes
CAS Number 70-00-8 YesY
ATC code S01AD02 (WHO)
PubChem CID 6256
DrugBank DB00432 YesY
ChemSpider 6020 YesY
KEGG D00391 YesY
Chemical data
Formula C10H11F3N2O5
Molar mass 296.2 g/mol
 NYesY (what is this?)  (verify)

Trifluridine (also called trifluorothymidine or TFT) is an anti-herpesvirus antiviral drug, used primarily on the eye. It was sold under the trade name, Viroptic, by Glaxo Wellcome, now merged into GlaxoSmithKline. The brand is now owned by Monarch Pharmaceuticals, which is wholly owned by King Pharmaceuticals.

It is a nucleoside analogue, a modified form of deoxyuridine, similar enough to be incorporated into viral DNA replication, but the -CF3 group added to the uracil component blocks base pairing, thus interfering with DNA replication.

It is a component of the experimental anti-cancer drug TAS-102.

A Cochrane Systematic Review showed that trifluridine was a more effective treatment than idoxuridine or vidarabine, significantly increasing the relative number of successfully healed eyes in 14 days.[1]


  1. ^ Wilhelmus KR (2010). "Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis". Cochrane Database Syst Rev. 12: CD002898. doi:10.1002/14651858.CD002898.pub4. PMID 21154352. 

External links[edit]

  • Costin D, Dogaru M, Popa A, Cijevschi I (2004). "Trifluridine therapy in herpetic in keratitis". Rev Med Chir Soc Med Nat Iasi. 108 (2): 409–12. PMID 15688823. 
  • Kuster P, Taravella M, Gelinas M, Stepp P (1998). "Delivery of trifluridine to human cornea and aqueous using collagen shields.". CLAO J. 24 (2): 122–4. PMID 9571274. 
  • O'Brien W, Taylor J (1991). "Therapeutic response of herpes simplex virus-induced corneal edema to trifluridine in combination with immunosuppressive agents.". Invest Ophthalmol Vis Sci. 32 (9): 2455–61. PMID 1907950. 
  • "Trifluridine Ophthalmic Solution, 1%" (PDF). Retrieved 2007-03-24.